Aomo Pharma Inc. (the US branch of Adamerck) is a biotechnology company cofound by Ph.D. Youmao Qi and Qing Jie in 2000. Since establishment, we are driven by a culture of innovation and commit to creating "better drugs for better lives". Based on proprietary technology platform AMCDx, we apply scientific expertise to develop and commercialize high-quality innovative drugs to meet unmet clinical needs.
We have a pipeline of more than 10 first-in-class drug candidates under development in anesthesia, cardiovascular diseases, eye diseases, neurodegenerative diseases and cancers. Adamgammadex (Aom0498) is one of all patented drug products, which is a best-in-class selective neuromuscular reversal agent. Two phase III pivotal clinical trials of adamgammadex in China have been completed and the NDA approval is expected to be received in China in 2024. The End-of-Phase II meeting with the US FDA on Adamgammadex has been held successfully on September 28, 2022. Multi-regional clinical trials (MRCT) in the US, Europe and Japan are scheduled to initiate in 2024.
Aomo Pharma Inc.
Discovering and developing effective, fast-acting and safe perioperative anesthesia drugs are the priority action for Aomo.
We are striving to develop new and effective therapeutic drugs for eye diseases.
Neuroprotective agent and medications for hypertrophic cardiomyopathy (HCM) are under development.
We strive to develop innovative drugs for treatment of most cancers and common side effects caused by existing cancer therapies.
Cancers
We are developing drug products for improving structure and function of the central nervous system or peripheral nervous system of patients with neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease.
|
|
